RCUS — Arcus Biosciences, Inc.
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1724521 ·
Last close
$23.83
Market Cap
$3.00B
52W High
$31.74
52W Low
$14.26
ADV30
1,588,496
Next earnings
2026-10-27
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 41,000,000 | — | -96,000,000 | -91,000,000 | 924,000,000 | 150,000,000 | 460,000,000 |
| Mar 2026 | 17,000,000 | — | -134,000,000 | -128,000,000 | 997,000,000 | 201,000,000 | 473,000,000 |
| Dec 2025 | 33,000,000 | — | -114,000,000 | -106,000,000 | 1,139,000,000 | 222,000,000 | 508,000,000 |
| Sep 2025 | 26,000,000 | — | -142,000,000 | -135,000,000 | 974,000,000 | 238,000,000 | 538,000,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-474,000,000
Investing CF
$63,000,000
Financing CF
$313,000,000
CapEx
$-3,000,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.90
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,704,000,000
Inventory
—
Receivables
$41,000,000
ST Investments
$552,000,000
EBIT TTM
$-449,000,000
Pretax Income TTM
$-460,000,000
Interest Exp TTM
$11,000,000
Analysts
12
Yahoo Snapshot (yfinance, live)
Total Revenue
$117,000,000
EBITDA
$-476,000,000
Free Cash Flow
$-270,624,992
Enterprise Value
$2,667,127,808
Total Cash
$702,000,000
Total Debt
$238,000,000
Shares Out
125,773,162
Trailing EPS
$-3.94
Book Value
$3.65
ROE
-90.8%
ROA
-30.4%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 247,000,000 | -386,000,000 | -353,000,000 | 1,139,000,000 | 508,000,000 | 631,000,000 | -482,000,000 |
| Dec 2024 | 258,000,000 | -310,000,000 | -283,000,000 | 1,150,000,000 | 665,000,000 | 485,000,000 | -170,000,000 |
| Dec 2023 | 117,000,000 | -340,000,000 | -307,000,000 | 1,095,000,000 | 633,000,000 | 462,000,000 | -306,000,000 |
| Dec 2022 | 112,000,000 | -280,000,000 | -267,000,000 | 1,345,000,000 | 688,000,000 | 657,000,000 | 438,000,000 |
TTM Snapshot
Revenues TTM
$236,000,000
NetIncome TTM
$-369,000,000
OpCashFlow TTM
—
Assets (Latest)
$997,000,000
Forward EPS
$-3.34
Max Pain — expiry 2026-10-16
max pain strike: $20.00 · spot: $24.48 · call oi: 9,525 · put oi: 1,113
Expected Move to 2026-10-16:
±$4.70
(19.20%) —
implied range
$19.78 –
$29.18
· ATM straddle on $25.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ELVN | Enliven Therapeutics, Inc. | $2.98B | $40.63 | — |
| AMLX | Amylyx Pharmaceuticals, Inc. | $3.03B | $27.20 | — |
| DYN | Dyne Therapeutics, Inc. | $3.06B | $16.37 | — |
| ARQT | Arcutis Biotherapeutics, Inc. | $3.08B | $24.49 | — |
| ZLAB | Zai Lab Ltd | $2.79B | $24.81 | — |
News headlines (Yahoo Finance, 1h cache)
Is Arcus Biosciences (RCUS) Undervalued As New Casdatifan Data Takes Center Stage?
2026-10-06 22:09 · Yahoo
Arcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of Therapy
2026-09-22 12:30 · Yahoo
Arcus Biosciences Announces New Employment Inducement Grants
2026-09-09 20:35 · Yahoo
Could Arcus Biosciences (RCUS) and Summit Therapeutics (SMMT)’s Cancer Drug Partnership Create a New Treatment Standard?
2026-08-14 00:03 · Yahoo
Arcus Biosciences (RCUS) Q2 2026 Earnings Call Transcript
2026-08-13 01:14 · Yahoo
Arcus Biosciences' Casdatifan Therapy Could be Launched in 2028, Morgan Stanley Says
2026-08-10 16:01 · Yahoo
Arcus Biosciences Q2 Earnings Call Highlights
2026-08-09 03:03 · Yahoo
Arcus Biosciences Reports Second-Quarter 2026 Financial Results and Provides a Pipeline Update
2026-08-05 20:05 · Yahoo
Arcus Biosciences, Inc. Q2 2026 Earnings Call Summary
2026-08-06 12:30 · Yahoo
How Investors Are Reacting To Arcus Biosciences (RCUS) Expansive New Casdatifan ARC-20 Kidney Cancer Data
2026-10-05 01:06 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.